These additional benefits may make it a particularly attractive option for patients with type 2 diabetes and other metabolic conditions
Glucagon receptor (present in survodutide and retatrutide, absent in tirzepatide): Glucagon receptor activation increases hepatic fat oxidation (the liver burns stored fat), raises resting energy expenditure by an estimated 150-200 kcal/day, and reduces hepatic lipid accumulation
Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss
For people with mild to moderate liver disease, semaglutide is usually considered safe, but regular liver tests may be recommended
Include quality protein foods at each meal i.e
Research Professor Department of Pathology & Biomedical Science University of Otago Christchurch, New Zealand Copyright 2000-2026 Linus Pauling Institute Figure Alternative Text Figure 1